The voluntary nationwide recall stems from elevated levels of impurity detected during recent routine quality testing. No adverse events have been reported. However, elevated impurities have the potential to result in neuromuscular blockage in patients with renal failure.
Affected lots were distributed between January and May 2012.
More Articles on Anesthesia:
California Society of Anesthesiologists Elects Dr. Peter Sybert President
Congress Looks at SGR Repeal, Must Also Tackle Anesthesiologists’ 33% Problem Prior
FDA Investigates Fungal Infection Associated with Tennessee Compounding Pharmacy
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.